The principle of the study is interesting, but the reliability of the results remains an important limitation. Indeed, the practices of German cardiologists have evolved during the study period. First, the PCI procedures are made more and more simple with more complex cases undertaken and a decreased morbidity (that is possibly the reason why the allcause mortality doubled during period when AMI, CABG and PCI are steady or decrease over time). On the other hand, the stents have become more efficient (comparing DES and BMS in 2008 is not the same as comparing DES and BMS in 2014) . Finally, the DRG system was modified during the studythe first years (2008) (2009) (2010) were under a convergence regime (Kovergenzphase) -and it is likely that some operators" choices (multivessel PCI at index versus staged PCI after 24 days) would impact the collected data.
State which events were included in MACCE and if the events where hierarchical ordered.
There are still some typos, systematic mistakes (drug-eluTing coronary stent) and awkward sentences.
I would suggest to accept the publication, but to complement with an editorial comment. Indeed, we will face more and more often this kind of "quality" analysis coming from the insurances or the national healthcare systems. These systems provide information on overall efficiency, but have a lot of bias and the data quality is highly variable. This was well illustrated at the initiation of the SCAAR register. The same holds certainly true for the UK NHS. The article summarizes the basic characteristics and clinical follow-up of insured German patients ongoing percutaneous coronary intervention with bare-metal coronary stent (BMS), drug-eluting coronary stent (DES), or bioresorbable vascular scaffolds (BVS) according to the German Diagnosis Related Groups encoded data for insurance reimbursement.
REVIEWER
The principle of the study is interesting, but the reliability of the results remains an important limitation. Indeed, the practices of German cardiologists have evolved during the study period. First, the PCI procedures are made more and more simple with more complex cases undertaken and a decreased morbidity (that is possibly the reason why the all-cause mortality doubled during period when AMI, CABG and PCI are steady or decrease over time). On the other hand, the stents have become more efficient (comparing DES and BMS in 2008 is not the same as comparing DES and BMS in 2014). Finally, the DRG system was modified during the study -the first years (2008) (2009) (2010) were under a convergence regime (Kovergenzphase) -and it is likely that some operators" choices (multivessel PCI at index versus staged PCI after 24 days) would impact the collected data.
We agree with the reviewer that practices have evolved during the study period for the reasons mentioned above. Therefore we performed a time trend analysis for the use of PCI procedures and we also describe separate annual event rates over the 7-year study period.
In the multivariable regression analysis comparing the BMS and DES groups the year of PCI treatment had been included as a possible confounder from the beginning. This had also been stated in the method section. To make this point clearer, we have also included this aspect in the discussion section, which now reads: "Because the practices of German cardiologists have evolved during the study period, we included the year of PCI treatment as a possible confounder in the multivariable regression analysis." (page 19).
MACCE include mortality, AMI, stroke and TIA (as stated on page 6). These events are not ordered hierarchically, i.e. the MACCE rate is the proportion of patients who had at least one of these events within the follow-up year. This information has been added to the definition on page 6.
We have had the manuscript checked by a native speaker.
I would suggest to accept the publication, but to complement with an editorial comment. Indeed, we will face more and more often this kind of "quality" analysis coming from the insurances or the national healthcare systems. These systems provide information on overall efficiency, but have a lot of bias and the data quality is highly variable. This was well illustrated at the initiation of the SCAAR register. The same holds certainly true for the UK NHS.
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Please leave your comments for the authors below.
This manuscript presents routine data analysis from 243581 PCI cases in the years 2008 to 2014 about the use of DES in the population of the largest (30 %) statutory health insurance in Germany. The carefully done analysis convincingly presents a lower MACCE rate for the PCI with DES.
The following comments may be allowed Introduction:
1. Please present the ESC-guidelines concerning application of DES, BMS and BVS.
We have modified the introduction accordingly (page 5).
Results: 2. I would recommend to start with the paragraph "Study population", followed by "Time trends in percutaneous coronary interventions", "MACCE and repeat-revascularization within one year"…..
We have changed the order of paragraphs accordingly (page 8, 10; 17,18 4. What about guideline adherence with respect to the indication for revascularization ("unresponsive to medical therapy")? Information about medical treatment of the patients would be helpful. Do you have a comparable group with medical therapy only?
We agree with the reviewer and have added this point to the limitation section: "Finally, routine data do not include detailed clinical information e.g. that needed to check whether indications conformed to the guidelines."
Discussion: 5. Page 16 lines 6-7: "Our data show that DES are associated with a decreased risk of 1-year MACCE compared to BMS." Please be a bit more careful: your statement is based on registry data and not on RCTs!
We agree with the reviewer and have changed the sentence to read: "Our data show that the use of DES has increased over time. 1-year MACCE are consistently less frequent than with BMS over the whole observation period" (pages 16) 6. Please compare your registry data representative for Germany with available data from other countries.
We have extended the discussion accordingly (page 18).
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GENERAL COMMENTS
Thank you for adequately responding to my comments. I agree with the revised manuscript.
